"documentVersion","studyEstimands","label","name","id","studyDesignRationale","bcCategories","studyInvestigationalInterventions","description","uuid:ID"
"","[]","","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","[]","The main design for the study","12699e10-8125-4871-81b8-60be53389aff"
